SEC Comment Letter 0000000000-22-013589 to TC BioPharm (Holdings) plc (TCBP, TCBPW) (CIK 0001872812) (TCBPY)

TC BioPharm (Holdings) plc (TCBP, TCBPW) (CIK 0001872812)
Date: Dec. 16, 2022 · CIK: 0001872812 · Accession: 0000000000-22-013589

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-268755

Date

December 16, 2022

Author

Not clearly detected

Form

UPLOAD

Company

TC BioPharm (Holdings) plc (TCBP, TCBPW) (CIK 0001872812)

Letter

United States securities and exchange commission logo December 16, 2022 Bryan Kobel Chief Executive Officer TC BioPharm (Holdings) plc Maxim 1, 2 Parklands Way Holytown, Motherwell, ML1 4WR Scotland, United Kingdom Re:TC BioPharm (Holdings) plc Registration Statement on Form F-1 Filed December 12, 2022 File No. 333-268755 Dear Bryan Kobel: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephen Cohen, Esq

Show Raw Text

United States securities and exchange commission logo
December 16, 2022
Bryan Kobel
Chief Executive Officer
TC BioPharm (Holdings) plc
Maxim 1, 2 Parklands Way
Holytown, Motherwell, ML1 4WR
Scotland, United Kingdom
Re:TC BioPharm (Holdings) plc
Registration Statement on Form F-1
Filed December 12, 2022
File No. 333-268755
Dear Bryan Kobel:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Stephen Cohen, Esq

SecProbe.io